Oncoinvent ASA (OSL:ONCIN) Other Current Payables: kr0.00 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSL:ONCIN Oncoinvent ASA OSL:ONCIN
36 GF Score
Price kr78.20
GF Value kr971.01
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Oncoinvent ASA Other Current Payables?

Oncoinvent ASA OSL:ONCIN +5.39% 36 Other Current Payables is kr0.00 Mil as of Dec. 2025. GuruFocus rates OSL:ONCIN with a GF Score™ of 36/100 and a GF Value™ of kr971.01 (Possible Value Trap). The stock has 5 warning signs investors should review.

Oncoinvent ASA's Other Current Payables for the quarter that ended in Dec. 2025 was kr0.00 Mil.

Oncoinvent ASA Other Current Payables Related Terms

Oncoinvent ASA Other Current Payables Historical Data

* Premium members only.

The historical data trend for Oncoinvent ASA's Other Current Payables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Oncoinvent ASA Other Current Payables Chart

Oncoinvent ASA Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Payables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Oncoinvent ASA Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Current Payables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
OSL:ONCIN
36GF Score
Oncoinvent ASA OSL:ONCIN
Other Current Payables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Oncoinvent ASA Other Current Payables Calculation

Other Current Payables is the payables owed and expected to be paid within one year or one operating cycle that not otherwise classified. It includes dividends payable and all other current payables.

Frequently Asked Questions Learn more about Other Current Payables →
What does a Other Current Payables of kr0.00 Mil mean?
Oncoinvent ASA (OSL:ONCIN) has a Other Current Payables of kr0.00 Mil as of Dec. 2025. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Oncoinvent ASA and its competitors.
Is Oncoinvent ASA's Other Current Payables too high?
Oncoinvent ASA's current Other Current Payables is kr0.00 Mil. Overall, Oncoinvent ASA has a GF Score™ of 36/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Oncoinvent ASA's Other Current Payables compare to VRTX and REGN?
Oncoinvent ASA's Other Current Payables of kr0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Payables for a Biotechnology company?
A good Other Current Payables depends on the Biotechnology industry context. However, Other Current Payables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Payables mean?
A high Other Current Payables can signal that a stock is expensive relative to its fundamentals. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Oncoinvent ASA and its competitors. Oncoinvent ASA's current Other Current Payables is kr0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oncoinvent ASA stock overvalued right now?
Based on GuruFocus' analysis, Oncoinvent ASA (OSL:ONCIN) is currently considered Possible Value Trap. The stock's GF Value™ is kr971.01, compared to a current price of kr78.20 — trading 91.9% below its estimated fair value. The current Other Current Payables is kr0.00 Mil. Oncoinvent ASA's overall GF Score™ is 36/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Payables calculated?
Other Current Payables is calculated from a company's financial statements. For Oncoinvent ASA (OSL:ONCIN), the current Other Current Payables is kr0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Oncoinvent ASA (OSL:ONCIN) Overvalued in 2026?

Based on GuruFocus' analysis, Oncoinvent ASA stock appears to be undervalued. The current stock price of kr78.20 is trading 91.9% below its estimated GF Value™ of kr971.01. GuruFocus considers Oncoinvent ASA to be Possible Value Trap.

Key valuation signals for OSL:ONCIN:

  • Other Current Payables: kr0.00 Mil
  • GF Value™: kr971.01 vs. price of kr78.20 (91.9% below fair value)
  • GF Score™: 36/100 with 5 warning signs

No single metric tells the full story. See the OSL:ONCIN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Oncoinvent ASA Business Description

Other Exchanges 0RU5:UK7BG:Germany
Address Gullhaugveien 7, Oslo, NOR, 0484
Oncoinvent ASA is a clinical-stage biotechnology company developing novel radiopharmaceutical therapies against cancer. Its key product candidate is Radspherin, a receptor-independent alpha radiation therapy that leverages the anatomy of the abdominal cavity to destroy residual micrometastases using a single, localized dose of alpha radiation. Radspherin is currently in clinical development in two indications: peritoneal metastasis from ovarian and colorectal cancer, but it is also relevant for treating peritoneal metastasis from other cancer types and potentially metastatic cancer in other body cavities. Geographically, the company operates in Norway.
36GF Score

Get the complete analysis for OSL:ONCIN

Other Current Payables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr78.20
Price
kr971.01
GF Value